Literature DB >> 17784887

Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment.

Heinrich Schulte-Baukloh1, Tomas H Zurawski, Helmut H Knispel, Kurt Miller, Axel Haferkamp, J Oliver Dolly.   

Abstract

OBJECTIVE To monitor the presence and cleavage of synaptosomal-associated protein of 25 kDa (SNAP-25) by botulinum toxin type A (botox-A), in human detrusor muscle, as the effects of botox-A in the urinary bladder last significantly longer than when applied for disorders of striated muscles. PATIENTS AND METHODS Tissue samples were obtained from eight patients with end-stage neurogenic bladder at different times after injection with botox-A. The resected bladder domes were examined using biochemical and immunohistological techniques. RESULTS The presence of intact SNAP-25 in human bladder was detected, for the first time, in all samples by both Western blotting and immunofluorescence. By contrast, detection of a band potentially representing toxin-cleaved SNAP-25(A) required its enrichment by precipitation with a specific antibody. This putative product was present in four of six patients treated with botox-A 5 weeks to 11 months previously, but could not be detected in one patient 30 months after botox injection, and in an untreated control. Fluorescence microscopy showed no obvious effects of the toxin treatment on the presence and pattern of SNAP-25-positive neurones. CONCLUSIONS A limited amount of SNAP-25 appears to be cleaved in nerves that innervate the smooth detrusor muscle in most patients who had been injected with botox-A; its absolute identification was precluded by the sensitivity of the detection. This protein was detectable much longer after toxin treatment than published for rodent striated muscle, and thus could contribute to the clinically reported longer duration of the effectiveness of botox-A.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17784887     DOI: 10.1111/j.1464-410X.2007.07137.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

Review 1.  Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.

Authors:  Todd A Linsenmeyer
Journal:  J Spinal Cord Med       Date:  2013-09       Impact factor: 1.985

Review 2.  [Botulinum toxin for neurogenic bladder dysfunction].

Authors:  H Schulte-Baukloh
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

Review 3.  How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?

Authors:  Maximilien Baron; Philippe Grise; Jean-Nicolas Cornu
Journal:  World J Nephrol       Date:  2016-03-06

Review 4.  Drug Insight: biological effects of botulinum toxin A in the lower urinary tract.

Authors:  Michael B Chancellor; Clare J Fowler; Apostolos Apostolidis; William C de Groat; Christopher P Smith; George T Somogyi; K Roger Aoki
Journal:  Nat Clin Pract Urol       Date:  2008-05-06

5.  Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.

Authors:  Ann T Hanna-Mitchell; Amanda S Wolf-Johnston; Stacey R Barrick; Anthony J Kanai; Michael B Chancellor; William C de Groat; Lori A Birder
Journal:  Neurourol Urodyn       Date:  2013-10-26       Impact factor: 2.696

Review 6.  The zinc-dependent protease activity of the botulinum neurotoxins.

Authors:  Frank J Lebeda; Regina Z Cer; Uma Mudunuri; Robert Stephens; Bal Ram Singh; Michael Adler
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

7.  BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study.

Authors:  Jacquie Maignel; Vincent Martin; Rana Assaly; Mathieu L Vogt; Kevin Retailleau; Fraser Hornby; Alexandra Laugerotte; Stéphane Lezmi; Pierre Denys; Johannes Krupp; Charles Joussain
Journal:  Toxins (Basel)       Date:  2022-01-21       Impact factor: 4.546

8.  Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome.

Authors:  Hsin-Tzu Liu; Sung-Ho Chen; Michael B Chancellor; Hann-Chorng Kuo
Journal:  PLoS One       Date:  2015-08-04       Impact factor: 3.240

Review 9.  BoNT/A in the Urinary Bladder-More to the Story than Silencing of Cholinergic Nerves.

Authors:  Hodan Ibrahim; Jacquie Maignel; Fraser Hornby; Donna Daly; Matthew Beard
Journal:  Toxins (Basel)       Date:  2022-01-12       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.